<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">319</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2019-13-4-46-53</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Bone marrow MRI after autologous transplantation and the effect of residual tumor on progression-free survival of multiple myeloma patients</article-title><trans-title-group xml:lang="ru"><trans-title>МРТ костного мозга после аутологичной трансплантации и влияние остаточной опухоли на выживаемость без прогрессии больных множественной миеломой</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7944-6202</contrib-id><name-alternatives><name xml:lang="en"><surname>Solovev</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Соловьев</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyy Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p>Максим Валерьевич Соловьев</p><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><email>maxsolovej@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4966-8146</contrib-id><name-alternatives><name xml:lang="en"><surname>Mendeleeva</surname><given-names>L. P.</given-names></name><name xml:lang="ru"><surname>Менделеева</surname><given-names>Л. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyy Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5085-4045</contrib-id><name-alternatives><name xml:lang="en"><surname>Yatsyk</surname><given-names>G. A.</given-names></name><name xml:lang="ru"><surname>Яцык</surname><given-names>Г. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyy Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7556-2054</contrib-id><name-alternatives><name xml:lang="en"><surname>Lutsik</surname><given-names>N. S.</given-names></name><name xml:lang="ru"><surname>Луцик</surname><given-names>Н. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyy Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4142-171X</contrib-id><name-alternatives><name xml:lang="en"><surname>Firsova</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Фирсова</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyy Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8357-977X</contrib-id><name-alternatives><name xml:lang="en"><surname>Gemdzhian</surname><given-names>E. G.</given-names></name><name xml:lang="ru"><surname>Гемджян</surname><given-names>Э. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyy Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8188-5557</contrib-id><name-alternatives><name xml:lang="en"><surname>Savchenko</surname><given-names>V. G.</given-names></name><name xml:lang="ru"><surname>Савченко</surname><given-names>В. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyy Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Research Center for Hematology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-12-03" publication-format="electronic"><day>03</day><month>12</month><year>2018</year></pub-date><volume>13</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>46</fpage><lpage>53</lpage><history><date date-type="received" iso-8601-date="2019-01-02"><day>02</day><month>01</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-01-02"><day>02</day><month>01</month><year>2019</year></date></history><permissions><copyright-year>2018</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/319">https://oncohematology.abvpress.ru/ongm/article/view/319</self-uri><abstract xml:lang="en"><p><bold><italic>Background . </italic></bold><italic>The study of influence of residual tumor mass, determined by magnetic resonance imaging (MRI), on the progression-free survival (PFS) remains an actual problem. Since the visual assessment of tumor bone marrow lesion can be one of the criteria for the subsequent personalized treatment choice in multiple myeloma patients.<bold/></italic></p><p><bold><italic>The objective </italic></bold><italic>of study was to determine the effect of bone marrow lesions detected by MRI after autologous hematopoietic stem cells transplantation (auto-HSCT) on PFS in multiple myeloma patients.<bold/></italic></p><p><bold><italic>Materials and methods . </italic></bold><italic>The prospective study included 60 patients who underwent spine and pelvic bones MRI on the 100 th day after autoHSCT.</italic></p><p><bold><italic>Results . </italic></bold><italic>Focal bone marrow changes were found in 47 of them – from 1 to 56 lesions (mean 6 ± 9). Significant (p = 0.01) differences of PFS in multiple myeloma patients depending on the presence or absence of tumor mass on 100 th day after auto-HSCT were revealed: with MRI negative status, 2-year PFS was 89 % versus 50 % in a group of patients with residual tumor mass.</italic></p><p><bold><italic>Conclusion . </italic></bold><italic>MRI-negative status after auto-HSCT is a favorable prognostic factor contributing to prolonged disease-free survival.<bold/></italic></p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Введение . </italic></bold><italic>Исследование влияния остаточной массы опухоли, определяемой по данным магнитно-резонансной томографии (МРТ), на показатели выживаемости без прогрессии (ВБП) остается актуальной задачей, поскольку визуальная оценка опухолевого поражения костного мозга может стать одним из критериев выбора последующего персонализированного лечения больных множественной миеломой.<bold/></italic></p><p><bold><italic>Цель исследования </italic></bold><italic>– определение влияния на показатели ВБП поражений костного мозга, выявленных методом МРТ после аутологичной трансплантации гемопоэтических стволовых клеток (ауто-ТГСК) у больных множественной миеломой.<bold/></italic></p><p><bold><italic>Материалы и методы . </italic></bold><italic>В проспективное исследование включены данные 60 больных, которым на 100-й день после ауто-ТГСК проводили МРТ-исследование позвоночника и костей таза.<bold/></italic></p><p><bold><italic>Результаты . </italic></bold><italic>Очаговые изменения костного мозга в количестве от 1 до 56 (медиана 6 ± 9) обнаружены у 47 пациентов. Сравнение показателей ВБП больных множественной миеломой в зависимости от наличия или отсутствия опухолевой массы на 100-й день после ауто-ТГСК выявило достоверные (p = 0,01) различия: при МРТ-отрицательном статусе 2-летняя ВБП составила 89 % против 50 % в группе больных с наличием остаточной опухолевой ткани.<bold/></italic></p><p><bold><italic>Заключение . </italic></bold><italic>МРТ-отрицательный статус после ауто-ТГСК является благоприятным прогностическим фактором, обусловливающим продолжительную выживаемость без признаков заболевания.<bold/></italic></p></trans-abstract><kwd-group xml:lang="en"><kwd>multiple myeloma</kwd><kwd>magnetic resonance imaging</kwd><kwd>autologous hematopoietic stem cells transplantation</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>множественная миелома</kwd><kwd>магнитно-резонансная томография</kwd><kwd>аутологичная трансплантация гемопоэтических стволовых клеток</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Roshal M., Flores-Montero J.A., Gao Q. et al. MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood 2017;1(12):728–32. DOI: 10.1182/bloodadvances.2016003715. PMID: 29296716.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Paiva B., Dongen J.J. M., Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 2015;125(20):3059–68. DOI: 10.1182/blood-2014-11-568907. PMID: 25838346.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kumar S., Paiva B., Anderson K.C. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17(8):e328–46. DOI: 10.1016/S1470-2045(16)30206-6. PMID: 27511158.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Flores-Montero J., Sanoja-Flores L., Paiva B. et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 2017;31(10):2094– 103. DOI: 10.1038/leu.2017.29. PMID: 28104919.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Solovev M., Mendeleeva L., Pokrovskaya O. et al. The duration of MRD-negative status in multiple myeloma (MM) patients after auto-HSCT is a criterion for prolonged remission without maintenance therapy. Blood 2017;130(Suppl. 1):3294.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Paiva B., Vidriales M.B., Cerveró J. et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112(10):4017–23. DOI: 10.1182/blood-2008-05-159624. PMID: 18669875.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Rawstron A.C., Child J.A., Tute R.M. et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013;31(20):2540–7. DOI: 10.1200/JCO.2012.46.2119. PMID: 23733781.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Roussel M., Lauwers-Cances V., Robillard N. et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo. J Clin Oncol 2014;32(25):2712–7. DOI: 10.1200/JCO.2013.54.8164. PMID: 25024076.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Dimopoulos M., Terpos E., Comenzo R.L. et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009;23(9):1545–56. DOI: 10.1038/leu.2009.89. PMID: 19421229.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Moulopoulos L.A., Gika D., Anagnostopoulos A. et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol 2005;16(11):1824–8. DOI: 10.1093/annonc/mdi362. PMID: 16087694.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Moulopoulos L.A., Dimopoulos М.А., Alexanian R. et al. Multiple myeloma: MR patterns of response to treatment. Radiology 1994;193(2):441–6. DOI: 10.1148/radiology.193.2.7972760. PMID: 7972760.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Bray T.J. P., Singh S., Latifoltojar A. et al. Diagnostic utility of whole body Dixon MRI in multiple myeloma: a multi-reader study. PLoS One 2017;12(7):e0180562. DOI: 10.1371/journal.pone.0180562. PMID: 28672007.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Lasocki A., Gaillard F., Harrison S.J. Multiple myeloma of the spine. Neuroradiol J 2017;30(3):259–68. DOI: 10.1177/1971400917699426. PMID: 28423980.</mixed-citation></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Dyrberg E., Hendel H.W., Al-Farra G. et al. A prospective study comparing whole-body skeletal X-ray survey with 18F-FDG-PET/CT, 18F-NaF-PET/CT and whole-body MRI in the detection of bone lesions in multiple myeloma patients. Acta Radiol Open 2017;6(10):2058460117738809. DOI: 10.1177/2058460117738809. PMID: 29123920.</mixed-citation><mixed-citation xml:lang="ru">Dyrberg E., Hendel H.W., Al-Farra G. et al. A prospective study comparing whole-body skeletal X-ray survey with 18F-FDG-PET/CT, 18F-NaF-PET/CT and whole-body MRI in the detection of bone lesions in multiple myeloma patients. Acta Radiol Open 2017;6(10):2058460117738809. DOI: 10.1177/2058460117738809. PMID: 29123920.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><mixed-citation>Filonzi G., Mancuso K., Zamagni E. et al. A comparison of different staging systems for multiple myeloma: can the MRI pattern play a prognostic role? AJR Am J Roentgenol 2017;209(1):152–8. DOI: 10.2214/AJR.16.17219. PMID: 28418695.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Moreau P., Attal M., Caillot D. et al. Prospective evaluation of magnetic resonance imaging and [18F] fluorodeoxyglucose positron emission tomographycomputed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial. J Clin Oncol 2017;35(25):2911–8. DOI: 10.1200/JCO.2017.72.2975. PMID: 28686535.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Hillengass J., Ayyaz S., Kilk K. et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica 2012;97(11):1757–60. DOI: 10.3324/haematol.2012.065359. PMID: 22689673.</mixed-citation></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Mendeleeva L.P., Votyakova O.M., Pokrovskaya O.S. et al. National clinical guidelines for the diagnosis and treatment of multiple myeloma. Gematologiya i transfuziologiya = Hematology and transfusiology 2016;61(1, Suppl. 2):1–24. (In Russ.). DOI: 10.18821/0234-5730-2016-61-1.</mixed-citation><mixed-citation xml:lang="ru">Менделеева Л.П., Вотякова О.М., Покровская О.С. и др. Национальные клинические рекомендации по диагностике и лечению множественной миеломы. Гематология и трансфузиология 2016;61(1, прил. 2):1–24. DOI: 10.18821/0234-5730-2016-61-1.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><mixed-citation>Sonneveld P., Avet-Loiseau H., Lonial S. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127(24):2955–62. DOI: 10.1182/blood-2016-01-631200. PMID: 27002115.</mixed-citation></ref></ref-list></back></article>
